LAVAL,
Quebec, April 4, 2022 /PRNewswire/ -- Bausch
Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its
gastroenterology (GI) business, Salix Pharmaceuticals
("Salix"), one of the largest specialty pharmaceutical companies in
the world committed to the prevention and treatment of
gastrointestinal diseases and disorders, today released the results
from the second edition of its Patient Perspectives Survey, an
annual survey of U.S adults living with irritable bowel syndrome
(IBS) or chronic idiopathic constipation (CIC). The current report,
Patient Perspectives: Living with IBS Now, offers a current
understanding of the behaviors and experiences of the IBS and CIC
patient population in the past year (February 2021 – February
2022), including insights on diagnosis and symptom
management. Most notably, almost half (49%) of respondents found
their IBS or CIC symptoms have been more challenging to manage
during the last 12 months. The report, which was developed based on
a nationwide survey conducted in partnership with the Farleigh
Dickinson University Poll (FDU Poll), also addresses gaps in
symptom management and reporting, and barriers to effective
treatment. The survey also reveals trends in patient-provider
communications.
Experience the interactive Multimedia News Release here:
https://www.multivu.com/players/English/9017851-salix-pharmaceuticals-survey-living-with-ibs-now/
"Salix remains committed to delivering impactful resources that
inform the entire IBS and CIC community and address the needs of
both patients and health care providers," said Robert Spurr, president, Salix. "The findings of
this year's report illustrate a need for more meaningful health
care provider visits to help improve clinical outcomes. As many as
3.5 million annual health care provider visits for IBS take place
in the U.S. each year1, and it is our hope that this
research will encourage productive dialogue and a collaborative
approach to symptom management and guideline-based treatment
options during these visits."
Key findings from the report include:
- Overall, 45% of patients acknowledged they began experiencing
IBS or CIC symptoms within the last 24 months
- More than three out of four patients surveyed report that
several of their IBS or CIC symptoms included in the survey have
not improved or have worsened over the last 12 months (between 77%
and 81% of respondents)
- 92% of HCP-diagnosed patients surveyed were initially diagnosed
with IBS or CIC during an in-person appointment with their health
care provider
- More than half (61%) of patients chose in-person visits as
their preferred method of communication with the health care
provider who treats their IBS or CIC
- When meeting with their health care provider, 40% of patients
shared they only discuss their main IBS or CICrelated symptom,
rather than discussing all IBS or CIC-related symptoms
- Nearly one-third (29%) of patients were not offered a
prescription medicine to treat symptoms upon diagnosis of their IBS
or CIC
To view key insights from Salix's Patient Perspectives:
Living with IBS Now report, visit here. To view a comprehensive
infographic, visit here.
About the Methodology Behind Patient Perspectives:
Living with IBS Now
Data is from a non-probability
online sample of U.S. residents and was carried out in February 2022 by Fairleigh
Dickinson University's FDU Poll. Participants were recruited
based on previously reported gastrointestinal issues. The overall
sample size of the survey was 728 respondents and was screened to
include only those who self-reported having IBS with constipation,
chronic idiopathic constipation or IBS with diarrhea. Respondents
were drawn from multiple panels of U.S. residents and were
compensated for their time (maximum $5.00). Due to the limitations of this survey,
results may not be representative of the general IBS or CIC
population.
About Fairleigh Dickinson
University
Since 2001, Fairleigh Dickinson
University's FDU Poll has conducted survey research on
issues of public importance. Utilizing best practices in survey
methodology, FDU Poll produces authoritative statewide and national
public polling. In addition, FDU Poll engages in research for
corporate, non-profit and government entities. As a charter member
of the American Association for Public Opinion
Research's Transparency Initiative, the FDU Poll is devoted to
building public confidence in polling by embracing the open science
of survey research.
About Salix
Salix Pharmaceuticals is one of the largest specialty
pharmaceutical companies in the world committed to the prevention
and treatment of gastrointestinal diseases. For more than 30 years,
Salix has licensed, developed and marketed innovative products to
improve patients' lives and arm health care providers with
life-changing solutions for many chronic and debilitating
conditions. Salix currently markets its product line to U.S. health
care providers through an expanded sales force that focuses on
gastroenterology, hepatology, pain specialists and primary care.
Salix is headquartered in Bridgewater, New Jersey. For more information about Salix,
visit www.Salix.com and connect with us
on Twitter and LinkedIn.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company
whose mission is to improve people's lives with our health care
products. We develop, manufacture and market a range of
pharmaceutical, medical device and over-the-counter products,
primarily in the therapeutic areas of eye health, gastroenterology,
and dermatology. We are delivering on our commitments as we build
an innovative company dedicated to advancing global health. More
information can be found at www.bauschhealth.com.
Forward-looking Statements
This news release may contain forward-looking statements, which may
generally be identified by the use of the words "anticipates,"
"expects," "intends," "plans," "should," "could," "would," "may,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risks and uncertainties discussed in the Bausch
Health's most recent annual report on Form 10-K and detailed from
time to time in Bausch Health's other filings with the U.S.
Securities and Exchange Commission and the Canadian Securities
Administrators, which factors are incorporated herein by reference.
They also include, but are not limited to, risks and uncertainties
caused by or relating to the evolving COVID-19 pandemic, and the
fear of that pandemic and its potential effects, the severity,
duration, and future impact of which are highly uncertain and
cannot be predicted, and which may have a material adverse impact
on Bausch Health, including but not limited to its project
development timelines, and costs (which may increase). Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements speak
only as of the date hereof. Bausch Health undertakes no obligation
to update any of these forward-looking statements to reflect events
or circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
References
- International Foundation for Gastrointestinal Disorders.
(n.d.).
Statistics. https://aboutibs.org/what-is-ibs/facts-about-ibs/statistics/
SAL.0024.USA.22
©2022 Salix Pharmaceuticals or its affiliates.
View original
content:https://www.prnewswire.com/news-releases/half-of-ibs-patients-surveyed-report-ibs-symptoms-more-challenging-to-manage-in-the-past-year-301516155.html
SOURCE Salix Pharmaceuticals